• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Synthetic Biology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast,2013 - 2019 Product Image

Synthetic Biology Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast,2013 - 2019

  • Published: April 2014
  • Region: Global
  • 143 Pages
  • Transparency Market Research
The global synthetic biology market is estimated to be USD 1,769.8 million in 2012 and is expected to reach USD 13,375.5 million by 2019, growing at a CAGR of 32.6% from 2013 to 2019.

FEATURED COMPANIES

  • Agrivida, Inc.
  • ATG:biosynthetics GmbH
  • Bristol-Myers Squibb
  • Evolva SA
  • GeneWorks Pty Ltd.
  • Ginkgo Bioworks
  • MORE

'Synthetic Biology Market (Synthetic DNA, Synthetic Genes, Synthetic Cells, XNA, Chassis Organisms, DNA Synthesis, Oligonucleotide Synthesis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast,2013 - 2019'

Synthetic biology defined as the synthesis of artificial or natural components in order to form new artificial living system by re-molding existing biological elements. It aims to attain new preferred functions of artificially modified organisms intended for high yield production of biological systems. Synthetic biology plays an important role in the field of life sciences by developing cheap synthesis procedures. Increasing scientific research coupled with introduction of advanced technologies in synthetic biology will drive the growth of this market.

The market for synthetic biology is segmented as: by products, by technologies and by applications. Product segment includes core products and enabling products. Core product segment comprises synthetic DNA, synthetic genes, synthetic cells, XNA and chassis organisms. While enabling products are segmented into DNA and oligonucleotide synthesis products.

Synthetic biology, by technologies segment READ MORE >

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 List of Abbreviations

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Synthetic Biology Market (2012 & 2019)
2.1.1 Global Synthetic Biology Market by Technologies, 2012 (USD Million)
2.2 Comparative Analysis: Global Synthetic Biology Market, By Geography, 2012 and 2019 (Value %)

Chapter 3 Market Overview
3.1 Introduction
3.2 Market Drivers
3.2.1 Drivers
3.2.1.1 Rising demand for improved drugs and vaccines
3.2.1.2 Advancement in molecular biology
3.2.1.3 Encouragement and participation of government bodies and universities in synthetic biology research
3.2.1.4 Increasing demand of genetically modified crops due to rising population
3.3 Market Restraints
3.3.1 Ethical Issues
3.4 Market Opportunities
3.4.1 Increasing clarity about metabolic pathways and nascent nature of synthetic biology concepts
3.5 Porter’s Five Force Analysis
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyers
3.5.3 Threat of Substitutes
3.5.4 Threat of New Entrants
3.5.5 Competitive Rivalry
3.6 Market Attractiveness Analysis: Global Synthetic Biology Market, by Geography

Chapter 4 Global Synthetic Biology Market, by Products
4.1 Introduction
4.1.1 Global Synthetic Biology Market Revenue, by Products, 2011 – 2019 (USD Million)
4.2 Core Products
4.2.1 Global Core Products Market Revenue, by Types, 2011 – 2019 (USD Million)
4.2.2 Synthetic DNA
4.2.2.1 Global Synthetic DNA Market Revenue, 2011 – 2019 (USD Million)
4.2.3 Synthetic Genes
4.2.3.1 Global Synthetic Genes Market Revenue, 2011 – 2019 (USD Million)
4.2.4 Synthetic Cells
4.2.4.1 Global Synthetic Cells Market Revenue, 2013 – 2019 (USD Million)
4.2.5 XNA (Xeno Nucleic Acid)
4.2.5.1 Global XNA Market Revenue, 2014 – 2019 (USD Million)
4.2.6 Chassis Organisms
4.2.6.1 Global Chassis Organisms Market Revenue, 2015 – 2019 (USD Million)
4.3 Enabling Products
4.3.1 Global Enabling Products Market Revenue, by Types, 2011 – 2019 (USD Million)
4.3.2 DNA Synthesis
4.3.2.1 Global DNA Synthesis Market Revenue, 2011 – 2019 (USD Million)
4.3.3 Oligonucleotide Synthesis
4.3.3.1 Global Oligonucleotide Synthesis Market Revenue, 2011 – 2019 (USD Million)

Chapter 5 Global Synthetic Biology Market, by Technologies
5.1 Introduction
5.1.1 Global Synthetic Biology Market Revenue, by Technologies, 2011 – 2019 (USD Million)
5.2 Genome Engineering
5.2.1 Global Genome Engineering in Synthetic Biology Market Revenue, 2011 – 2019 (USD Million)
5.3 DNA Sequencing
5.3.1 Global DNA Sequencing in Synthetic Biology Market Revenue, 2011 – 2019 (USD Million)
5.4 Bioinformatics
5.4.1 Global Bioinformatics in Synthetic Biology Market Revenue, 2011 – 2019 (USD Million)
5.5 Biological Components and Integrated Systems
5.5.1 Global Biological Components and Integrated Systems in Synthetic Biology Market revenue, 2011 – 2019 (USD Million)

Chapter 6 Global Synthetic Biology Market, by Applications
6.1 Introduction
6.1.1 Global Synthetic Biology Market Revenue, by Applications, 2011 – 2019 (USD Million)
6.2 Chemicals
6.2.1 Global Synthetic Biology in Chemicals, Market Revenue, 2011 – 2019 (USD Million)
6.3 Healthcare
6.3.1 Global Synthetic Biology in Healthcare Market Revenue, 2011 – 2019 (USD Million)
6.4 Agriculture
6.4.1 Global Synthetic Biology in Agriculture Market Revenue, 2011 – 2019 (USD Million)
6.5 Others (Biosecurity, R&D, Energy and Environment)
6.5.1 Global Synthetic Biology in Other Applications Market Revenue, 2011 – 2019 (USD Million)

Chapter 7 Global Synthetic Biology Market, by Geography
7.1 Introduction
7.1.1 Global Synthetic Biology Market Revenue, by Geography, 2011 – 2019 (USD Million)
7.2 North America
7.2.1 North America Synthetic Biology Market Revenue, 2011 – 2019 (USD Million)
7.3 Europe
7.3.1 Europe Synthetic Biology Market Revenue, 2011 – 2019 (USD Million)
7.4 Asia-Pacific
7.4.1 Asia-Pacific Synthetic Biology Market Revenue, 2011 – 2019 (USD Million)
7.5 Rest of the World (RoW)
7.5.1 RoW Synthetic Biology Market Revenue, 2011 – 2019 (USD Million)

Chapter 8 Competitive Landscape
8.1 Heat Map Analysis for Key Market Players
8.1.1 Amyris, Inc.
8.1.2 DuPont, Inc.
8.1.3 Royal DSM
8.1.4 Evolva Holding
8.1.5 Life Technologies Corporation
8.2 Heat Map Analysis of the Synthetic Biology Market, by Key Market Players, 2013

Chapter 9 Recommendations
9.1 Market Strategy for Success
9.1.1 Focus on investing in research and development activities
9.1.2 Strategic alliance, mergers and acquisitions
9.2 Barriers to be Considered
9.2.1 Ethical issues associated with synthetic biology products

Chapter 10 Company Profiles
10.1 Agrivida, Inc.
10.1.1 Company Overview
10.1.2 Financial Overview
10.1.3 Product Portfolio
10.1.4 Business Strategies
10.1.5 Recent Developments
10.2 Amyris, Inc.
10.2.1 Company Profile
10.2.2 Financial Overview
10.2.3 Product Portfolio
10.2.4 Business Strategies
10.2.5 Recent Developments
10.3 Algenol Biofuels, Inc.
10.3.1 Company Overview
10.3.2 Financial Overview
10.3.3 Product Portfolio
10.3.4 Business Strategies
10.3.5 Recent Developments
10.4 ATG:biosynthetics GmbH
10.4.1 Company Overview
10.4.2 Financial Overview
10.4.3 Product Portfolio
10.4.4 Business Strategies
10.4.5 Recent Developments
10.5 Bayer AG
10.5.1 Company Overview
10.5.2 Financial Overview
10.5.3 Product Portfolio
10.5.4 Business Strategies
10.5.5 Recent Developments
10.6 Bristol-Myers Squibb
10.6.1 Company Overview
10.6.2 Financial Overview
10.6.3 Product Portfolio
10.6.4 Business Strategies
10.6.5 Recent Developments
10.7 BIONEER CORPORATION
10.7.1 Company Overview
10.7.2 Product Portfolio
10.7.3 Business Strategies
10.7.4 Recent Developments
10.8 Biosearch Technologies, Inc.
10.8.1 Company Overview
10.8.2 Financial Overview
10.8.3 Product Portfolio
10.8.4 Business Strategies
10.8.5 Recent Developments
10.9 CBC Comprehensive Biomarker Center GmbH
10.9.1 Company Overview
10.9.2 Financial Overview
10.9.3 Product Portfolio
10.9.4 Business Strategies
10.9.5 Recent Developments
10.10 Cobalt Technologies
10.10.1 Company Overview
10.10.2 Financial Overview
10.10.3 Product Portfolio
10.10.4 Business Strategies
10.10.5 Recent Developments
10.11 DuPont, Inc.
10.11.1 Company Overview
10.11.2 Financial Overview
10.11.3 Product Portfolio
10.11.4 Business Strategies
10.11.5 Recent Developments
10.12 Evolva SA
10.12.1 Company Overview
10.12.2 Financial Overview
10.12.3 Product Portfolio
10.12.4 Business Strategies
10.12.5 Recent Developments
10.13 Exxon Mobil Corporation
10.13.1 Company Overview
10.13.2 Financial Overview
10.13.3 Product Portfolio
10.13.4 Business Strategies
10.13.5 Recent Developments
10.14 Ginkgo Bioworks
10.14.1 Company Overview
10.14.2 Financial Overview
10.14.3 Product Portfolio
10.14.4 Business Strategies
10.14.5 Recent Developments
10.15 GeneWorks Pty Ltd.
10.15.1 Company Overview
10.15.2 Financial Overview
10.15.3 Product Portfolio
10.15.4 Business Strategies
10.15.5 Recent Developments
10.16 Genomatica, Inc.
10.16.1 Company Overview
10.16.2 Financial Overview
10.16.3 Product Portfolio
10.16.4 Business Strategies
10.16.5 Recent Developments
10.17 GeneScript Corporation
10.17.1 Company Overview
10.17.2 Financial Overview
10.17.3 Product Portfolio
10.17.4 Business Strategies
10.17.5 Recent Developments
10.18 Gevo, Inc.
10.18.1 Company Overview
10.18.2 Financial Overview
10.18.3 Product Portfolio
10.18.4 Business Strategies
10.18.5 Recent Developments
10.19 Green Biologics Limited
10.19.1 Company Overview
10.19.2 Financial Overview
10.19.3 Product Portfolio
10.19.4 Business Strategies
10.19.5 Recent Developments
10.20 New England Biolabs, Inc.
10.20.1 Company Overview
10.20.2 Financial Overview
10.20.3 Product Portfolio
10.20.4 Business Strategies
10.20.5 Recent Developments
10.21 OriGene Technologies, Inc.
10.21.1 Company Overview
10.21.2 Financial Overview
10.21.3 Product Portfolio
10.21.4 Business Strategies
10.21.5 Recent Developments
10.22 REG Life Sciences, LLC
10.22.1 Company Overview
10.22.2 Financial Overview
10.22.3 Product Portfolio
10.22.4 Business Strategies
10.22.5 Recent Developments
10.23 Royal DSM
10.23.1 Company Overview
10.23.2 Financial Overview
10.23.3 Product Portfolio
10.23.4 Business Strategies
10.23.5 Recent Developments
10.24 Thermo Fisher Scientific, Inc.
10.24.1 Company Overview
10.24.2 Financial Overview
10.24.3 Product Portfolio
10.24.4 Business Strategies
10.24.5 Recent Developments

List of Figures

Figure 1 Synthetic Biology Market Segmentation
Figure 2 Global Synthetic Biology Market, by Technologies, 2012 (USD Million)
Figure 3 Comparative Analysis: Global Synthetic Biology Market, by Geography, 2012 and 2019 (Value %)
Figure 4 Porter’s Five Forces Analysis: Global Synthetic Biology Market
Figure 5 Market Attractiveness Analysis: Global Synthetic Biology Market, by Geography
Figure 6 Global Synthetic DNA Market Revenue, 2011 – 2019 (USD Million)
Figure 7 Global Synthetic Genes Market Revenue, 2011 – 2019 (USD Million)
Figure 8 Global Synthetic Cells Market Revenue, 2013 – 2019 (USD Million)
Figure 9 Global XNA Market Revenue, 2014 – 2019 (USD Million)
Figure 10 Global Chassis Organisms Market Revenue, 2015 – 2019 (USD Million)
Figure 11 Global DNA Synthesis Market Revenue, 2011 – 2019 (USD Million)
Figure 12 Global Oligonucleotide Synthesis Market Revenue, 2011 – 2019 (USD Million)
Figure 13 Global Genome Engineering in Synthetic Biology Market Revenue, 2011 – 2019 (USD Million)
Figure 14 Global DNA Sequencing in Synthetic Biology Market Revenue, 2011 – 2019 (USD Million)
Figure 15 Global Bioinformatics in Synthetic Biology Market Revenue, 2011 – 2019 (USD Million)
Figure 16 Global Biological Components and Integrated Systems in Synthetic Biology Market Revenue, 2011 – 2019 (USD Million)
Figure 17 Global Synthetic Biology in Chemicals Market Revenue, 2011 – 2019 (USD Million)
Figure 18 Global Synthetic Biology in Healthcare Market Revenue, 2011 – 2019 (USD Million)
Figure 19 Global Synthetic Biology in Agriculture Market Revenue, 2011 – 2019 (USD Million)
Figure 20 Global Synthetic Biology in Other Applications Market Revenue, 2011 – 2019 (USD Million)
Figure 21 North America Synthetic Biology Market Revenue, 2011 – 2019 (USD Million)
Figure 22 Europe Synthetic Biology Market Revenue, 2011 – 2019 (USD Million)
Figure 23 Asia-Pacific Synthetic Biology Market Revenue, 2011 – 2019 (USD Million)
Figure 24 RoW Synthetic Biology Market Revenue, 2011 – 2019 (USD Million)
Figure 25 Heat Map Analysis of the Synthetic Biology Market, by Key Market Players, 2013
Figure 26 Amyris, Inc.: Annual Revenue, 2010 – 2012 (USD Million)
Figure 27 Bayer AG: Annual Revenue, 2011 – 2013 (USD Million)
Figure 28 Bristol-Myers Squibb: Annual Revenue, 2011 – 2013 (USD Million)
Figure 29 DuPont, Inc.: Annual Revenue, 2010– 2012 (USD Million)
Figure 30 Evolva SA: Annual Sales, 2010 – 2012 (USD Million), 1 CHF = 1.13 USD
Figure 31 Exxon Mobil Corporation: Annual Sales, 2010 – 2012 (USD Billion)
Figure 32 Gevo, Inc.: Annual Sales, 2010 – 2012 (USD Million)
Figure 33 Renewable Energy Group, Inc.: Annual Sales, 2011 – 2013 (USD Million)
Figure 34 Royal DSM: Annual Revenue, 2010– 2012 (USD Million)
Figure 35 Thermo Fisher Scientific, Inc.: Annual Revenue, 2010 – 2012 (USD Million)

List of Tables

Table 1 List of Abbreviations
Table 2 Market Snapshot: Global Synthetic Biology Market (2012 & 2019)
Table 3 Global Synthetic Biology Market Revenue, by Products, 2011 – 2019 (USD Million)
Table 4 Global Core Products Market Revenue, by Types, 2011 – 2019 (USD Million)
Table 5 Global Enabling Products Market Revenue, by Types, 2011 – 2019 (USD Million)
Table 6 Global Synthetic Biology Market Revenue, by Technologies, 2011 – 2019 (USD Million)
Table 7 Global Synthetic Biology Market Revenue, by Applications, 2011 – 2019 (USD Million)
Table 8 U.S. Bio-fuels Pipeline Products, by Organizations
Table 9 Developed Drugs and Vaccines Utilizing the Concept of Synthetic Biology
Table 10 Global Synthetic Biology Market Revenue, by Geography, 2011 – 2019 (USD Million)
Table 11 List of Organizations and their Synthetic Biology Products and Applications

Synthetic biology is a synergistic combination of biology and engineering for the construction of artificial biological system in order to gain desired functions (i.e. to reduce cost or improve efficacy). It comprises nascent technologies that enable synthesis of novel biological parts and organisms that are used in the field of healthcare, chemicals, agriculture and others (biosecurity, R&D and energy and environment).

The synthetic biology market is witnessing rapid growth owing to increase in demand for renewable fuels and bio-based chemicals and inexpensive drugs and vaccines that utilizes synthetic biology technologies and products. In addition, participation of various organizations such as BioBricks, DIYbio and SynBERC, for the development of synthetic biology field will further augment the growth of this market during the forecast period. However, high cost and strict regulations to use synthetic biology techniques hampers the growth of this market.

Synthetic biology market is segmented mainly by products, by technologies and by applications. Synthetic biology, by product segment is classified as core products and enabling products. Core products are further segmented into synthetic DNA, synthetic genes, synthetic cells, XNA and chassis organisms. The synthetic biology market by core products was dominated by synthetic DNA market in 2012 owing to the commercial availability of this product, compared to other synthetic core products expected to be launched in the market in coming years.

Synthetic biology market by technologies is segmented as genome engineering, DNA sequencing, bioinformatics and biological components and integrated systems. Genome engineering technology can be used to modify genetic foods, gene cloning and gene therapy. Thus, application of genome engineering increases the scope to utilize this technique and hence accentuates the growth of this market.

Applications of synthetic biology are healthcare, chemicals, agriculture and others. Synthetic biology in healthcare holds largest market share in terms of revenue due to high utilization of synthetic biology techniques to produce cheap drugs and vaccines. Also, commercial availability of synthetic DNA and synthetic genes supports the growth of the healthcare application in the synthetic biology market. Agriculture segment is expected to grow at the highest growth rate during the forecast period.

Europe contributed the largest share of the global synthetic biology market in 2012 and is expected to grow consistently, owing to increasing efforts of government and private organizations towards the development of this field. North America contributed the second largest share of the total market in 2012. Introduction of novel technologies by will help the growth of this market in North America. The Asia-Pacific region is expected to witness the fastest growth due to support of international organizations (e.g. Biotechnology Industry Organization and others) for the growth of synthetic biology in Asia-Pacific.

In terms of key players, the global synthetic biologymarket is highly fragmented with presence of a large number of players that includeBristol Mayer, Gevo, Inc., Life Technologies, DSM, DuPont, Inc., Genomatica, Inc., LS9, Inc.,Amyris, Inc. and others.

- Agrivida, Inc.
- Amyris, Inc.
- Algenol Biofuels, Inc.
- ATG:biosynthetics GmbH
- Bayer AG
- Bristol-Myers Squibb
- BIONEER CORPORATION
- Biosearch Technologies, Inc.
- CBC Comprehensive Biomarker Center GmbH
- Cobalt Technologies
- DuPont, Inc.
- Evolva SA
- Exxon Mobil Corporation
- Ginkgo Bioworks
- GeneWorks Pty Ltd.
- Genomatica, Inc.
- GeneScript Corporation
- Gevo, Inc.
- Green Biologics Limited
- New England Biolabs, Inc.
- OriGene Technologies, Inc.
- REG Life Sciences, LLC
- Royal DSM
- Thermo Fisher Scientific, Inc.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos